Short Interest in Cosmo Pharmaceuticals (OTCMKTS:CMOPF) Decreases By 32.4%

Cosmo Pharmaceuticals (OTCMKTS:CMOPF) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 7,450 shares, a decline of 32.4% from the August 15th total of 11,024 shares. Based on an average trading volume of 447 shares, the days-to-cover ratio is presently 16.7 days.

Cosmo Pharmaceuticals Stock Performance

CMOPF opened at C$64.92 on Thursday. The stock’s fifty day simple moving average is C$73.84 and its 200 day simple moving average is C$93.02. Cosmo Pharmaceuticals has a 1-year low of C$63.49 and a 1-year high of C$169.90.

Cosmo Pharmaceuticals Company Profile

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.